Exelixis (EXEL) Earning Somewhat Favorable News Coverage, Report Finds
News coverage about Exelixis (NASDAQ:EXEL) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exelixis earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.3079850816629 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Exelixis Slides Despite Positive Late-Stage Results (feedproxy.google.com)
- Oppenheimer Reaffirms Hold Rating for Exelixis (EXEL) (americanbankingnews.com)
- Diplomat Pharmacy begins distribution of Exelixis’ Cabometyx to treat patients with advanced RCC (pharmabiz.com)
- Exelixis, Ipsen Report Positive Results on Lead Cancer Drug (finance.yahoo.com)
- Exelixis, Ipsen report cancer drug success in late-stage study (seekingalpha.com)
Exelixis (NASDAQ EXEL) traded down $2.16 on Wednesday, hitting $27.49. 7,710,000 shares of the stock were exchanged, compared to its average volume of 2,590,000. The stock has a market capitalization of $8,130.00, a price-to-earnings ratio of 56.10, a P/E/G ratio of 0.91 and a beta of 1.88. Exelixis has a 12 month low of $16.72 and a 12 month high of $32.50.
Several research firms recently commented on EXEL. Oppenheimer restated a “hold” rating on shares of Exelixis in a report on Thursday, January 4th. Cann reiterated a “hold” rating on shares of Exelixis in a research note on Thursday, January 4th. Needham & Company LLC lifted their price objective on shares of Exelixis from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, October 17th. Royal Bank of Canada lifted their price objective on shares of Exelixis from $33.00 to $39.00 and gave the company an “outperform” rating in a research note on Tuesday, October 17th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $26.00 price objective on shares of Exelixis in a research note on Tuesday, October 17th. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $32.13.
In related news, Director Alan M. Garber sold 15,000 shares of Exelixis stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the sale, the director now owns 64,829 shares in the company, valued at $1,964,318.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 5.10% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Exelixis (EXEL) Earning Somewhat Favorable News Coverage, Report Finds” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/01/17/exelixis-exel-earning-somewhat-favorable-news-coverage-report-finds.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.